SUPPORT HOTLINE (888) 901-2226
Donate Now

BRIEF TITLE: Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach

Genetic Susceptibility to Bladder Cancer: A Molecular Epidemiology Approach


  • Org Study ID: LAB98-040
  • Secondary ID: LAB98-040,5P50CA091846-14,H-8577,5R01CA074880
  • NCT ID: NCT00848289
  • NCT Alias:
  • Sponsor: M.D. Anderson Cancer Center - Other
  • Source: M.D. Anderson Cancer Center

Brief Summary

This clinical research study will identify biologic and lifestyle factors which increase a person's risk of developing specific cancer. Researchers propose to conduct a case-control study examining interindividual differences in susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic modulation of carcinogen activation and detoxification and of chromosome sensitivity to tobacco mutagens.

Detailed Description


Researchers propose to conduct a case-control study examining interindividual differences in
susceptibility to tobacco carcinogenesis as predictors of bladder cancer risk. We will
measure susceptibility to tobacco carcinogenesis and this will include studies of the genetic
modulation of carcinogen activation and detoxification and of chromosome sensitivity to
tobacco mutagens.

Overal Status Start Date Phase Study Type
Recruiting February 10, 1998 Observational

Primary Outcomes:

Primary Outcome 1 - Measure: Comparison of mutagen sensitivity susceptibility assays that quantifies the number of lymphocytic chromatid breaks induced by in vitro exposure to bleomycin and the number of breaks induced by in vitro exposure to a tobacco carcinogen

Primary Outcome 1 - Time Frame: After last subject has completed the study, up to 5 years

Condition:

  • Bladder Cancer

Eligibility

Criteria:
Inclusion Criteria:

- Subject has a histologically confirmed diagnosis of superficial or muscle-invasive
bladder cancer

- Subject is a Texas resident.

- Subject can understand English or a qualified translator is available for the
interview.

- Subjects of any age, gender, or ethnicity are eligible to participate in the study.

- Subject consents to participate in the study.

Exclusion Criteria:

- Subject has had prior treatment with systemic chemotherapy or radiotherapy in the past
6 months.

- Subject has been diagnosed with superficial or muscle-invasive bladder cancer more
than twelve months ago.
Show More

Gender: All

Minimum Age: N/A

Maximum Age: N/A

Healthy Volunteers: Accepts Healthy Volunteers

Official Information

Name: Jian Gu, MD

Role: Principal Investigator

Affiliation: M.D. Anderson Cancer Center

Overall Contact

Name: Jian Gu, MD

Phone: 713-792-3020

Email: jiangu@mdanderson.org

Link: The University of Texas (UT) MD Anderson Cancer Center Official Website

Locations

Facility Status Contact
Baylor College of Medicine
Houston, Texas 77030
United States
Terminated
MD Anderson Cancer Center
Houston, Texas 77030
United States
Recruiting Xifeng Wu, MD
713-792-3020
xwu@mdanderson.org